Novomer Wins InformexUSA Sustainability Award
BOSTON, MA--(Marketwire - February 9, 2011) - Novomer Inc., a sustainable materials company pioneering a family of high-performance plastics, polymers and other chemicals from renewable feedstocks such as carbon dioxide (CO2), today announced that it has been recognized with a InformexUSA 2011 Profiles in Sustainability Award. Novomer was honored during the show's awards gala held last night at the Charlotte Convention Center.
Affinnova Triples the Likelihood of Beating Leading Competitors
Waltham, MA, February 09, 2011 – Affinnova, the global leader in marketing innovation software and services, today announced that 64% of client initiatives using their IDDEA software produce optimized concepts that outscore their leading competitor. Conversely, pre-optimization concepts from the same initiatives beat their leading competitor only 22% of the time. These findings are the result of a yearlong study of all client initiatives using Affinnova’s IDDEA II software with competitive benchmark measurement capabilities.
LS9 Announces Second Partnership with Procter & Gamble
SOUTH SAN FRANCISCO, CA - February 7, 2011 - LS9, Inc. today announced the initiation of a second development and commercialization partnership with Procter & Gamble (NYSE: PG). This additional partnership draws on LS9's unique technology to broaden the portfolio of renewable chemicals to be used in P&G's consumer products.
BD Announces Agreement to Acquire Accuri Cytometers, Inc.
BG Medicine Announces Pricing of Initial Public Offering
WALTHAM, Mass.--(BUSINESS WIRE)--BG Medicine (NASDAQ: BGMD) today announced the pricing of its initial public offering of 5,000,000 shares of its common stock at a price of $7.00 per share, before underwriting discounts and commissions. All shares are being sold by the Company.
AVEO Pharmaceuticals Initiates Enrollment in a Phase 2 Exploratory Biomarker Study of Tivozanib
CAMBRIDGE, Mass., Feb 01, 2011 (BUSINESS WIRE) -- AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) today announced that it has initiated patient enrollment in a multi-center Phase 2 exploratory biomarker study of tivozanib, its lead product candidate designed to optimally block the VEGF pathway by inhibiting all three VEGF receptors, in patients with renal cell carcinoma (RCC).
Joule Biotechnologies Names Bill Sims President and CEO
Cambridge, Mass.—July 27, 2009—Joule Biotechnologies, Inc., an innovative bioengineering startup developing game-changing alternative energy solutions, today announced the appointment of Bill Sims as president and CEO. Sims brings nearly 30 years of experience growing both emerging and established companies across multiple technology and product sectors. In addition to his new position, he will continue to serve on the company’s board of directors.
Mascoma Announces Feedstock Processing and Lignin Supply Agreement with Chevron Technology Ventures
Lebanon, New Hampshire – September 14, 2009 – Mascoma Corporation today announced that it has entered into a feedstock processing and lignin supply agreement with Chevron Technology Ventures (CTV), a division of Chevron U.S.A., Inc.
Under terms of the agreement, CTV will provide various sources of lignocellulosic feedstock to Mascoma. Mascoma will then convert the feedstock to cellulosic ethanol through its proprietary process, which produces lignin as a by-product. Mascoma will provide this lignin to CTV for evaluation.
VisEn Launches New Cat B 680 FAST™ Fluorescence Molecular Imaging Agent
Extends VisEn’s Leading Fluorescence Molecular Imaging Agent Portfolio to Enable Expanded Readouts of Key Protease Biomarkers in Research and Drug Development
BEDFORD, MA (January 19, 2010)—VisEn Medical Inc., a leader in fluorescence in vivo imaging from research through medicine, announced today the commercial launch of its new Cat B 680 FAST™ imaging agent for measuring and monitoring cathepsin B activity associated with disease progression and therapeutic response in vivo.
Receptos Initiates Clinical Trials for S1P1 Agonist Program, Aimed at Multiple Sclerosis
First subject dosed in Phase 1 Single Ascending and Multiple Ascending Dose Safety Study